PMED is my next pick after confirmation of a reversal on different levels, the previous issues are now settled and over and is about to get more attention. I am playing this as a short to mid term (under 3 months for now but that could change) only since I lack the info to confirm holding long as of yet. Same sector as CLBE but in another division. In no way do I see this as equal to CLBE but I speculate it should reach the upper single pennies fairly easy. They also have a smaller OS at approximately 28 mill but the AS eventually could reach 250m which is still modest but stocks like AMEP with almost 400m OS and 500AS easily shows you how they can move in the right sector and the energy and bio tech /med sectors are getting to be focused on throughout the season and thru the last quarter of this year. Looking at the chart for this you can easily see what I mean if your into charting. My opinion of a good entry here is anywhere from here to .03 to safely cover your double mark at my projected target of .06 (but that to can changed)
As you can see by the T/A chart it’s just beginning to start the reversal cycle and coming off an all time low now.
There’s also an alert going out now from Morning Star and just been rated a buy from American Bulls (if anyone cares about them at all…LOL) and also from another poster that has been pretty inquisitive.
“Revenue of over $3 million and they have over $1 million in cash. Just based on that, the company should be at $0.038. Only $2.5 million in debt, so it's not like they are grossly in debt or anything. Looks like the lawsuit has held this one down. Not much downside on this one”
As usual do your own DD on this as you have on the rest of my picks, do not buy off anyone else’s post or mine without verifying any info you may find and do not forget to target your principal first.
Q
Posted by HitMe101 on :
& Moving now!
Posted by BULListic on :
I got my 200k at $.01...you know I like this one!! Agree Quest totally on where this one should go in the next few weeks/months.
Posted by HitMe101 on :
Strong support on Bid also unlike some of those picks this a.m. Nice one.
Posted by QuestSolver on :
BULListic...hope you don"t mine I used one of your post.
Posted by BULListic on :
I got my 200k at $.01...you know I like this one!! Agree Quest totally on where this one should go in the next few weeks/months.
Posted by BULListic on :
No problem Quest...thanks also to JimSC who brought this one up yesterday....always looking for that "solid" company selling for a penny, a penny doesn't go as far as it used too! So finding these gems at the bottom is hard but very worthwhile, especially when they have a viable business plan and not just some empty shell.
Posted by doling2005 on :
Level 2 anyone?
Posted by QuestSolver on :
trying to get another buy on this dip,setting for .0135,.014 and .015 for 100k each.
Posted by Slippery Wing on :
Looks like a good pick, Quest.
Posted by QuestSolver on :
I am thinking this touches the .03 mark today
Posted by Slippery Wing on :
That's pretty optimistic....
Posted by Slippery Wing on :
I'll wait for the pull back from the early morning run.... And then see what happens....
Posted by HitMe101 on :
With the exposure this a.m. & the volume continuing,it is very possible.Looking to break down .02
Posted by QuestSolver on :
L2 is setting up nice for a run,raised tow buys to .0165 which executed and the low side at .0138 for 250k for a long shot.
Posted by doling2005 on :
Looks like it could be up from here for good following that news?
Posted by QuestSolver on :
also PMED based out and is line for another upward move,should touch .03 today if all stays consistant
Posted by QuestSolver on :
trust your own experience,remember last week when CLBE was trading identical to this? B/A matching and so forth and each buy or sell reflects immediately? This is only day one of a few more left for good entries.I have an AON buy set at the ask with no execution at all,tells me the MM's have little storage and are looking for mirrors to move this...good sign!
Posted by QuestSolver on :
be back soon,gotta make some calls in the central time zone Posted by Slippery Wing on :
Well stabilized in the 0.015 range
Posted by QuestSolver on :
just got off the phone with John Uoon,he is head of the IR dept..we can expect an earnings release within 4 weeks but apparently somethings in the works but they could not go into it until its made public (which is pretty much what I expected...LOL) as I have said before,post picks early and load up for the real runs but this so far is still a short to mid term play for me until further notice.
lunchtime lull has begum
Posted by mmalone on :
Following your lead Quest. Did some basic DD, definately looks undervalued. Market cap of $425K is extremely low for a company producing $3 Million in revenues annually, even if it's not profitable. Definately looks like the PPS drop was due to the lawsuit that has been settled.
GLTA, -Mike
Posted by BULListic on :
Emerging Stock Report: Paradigm Looking Forward Again 10/11/05
Oct 11, 2005 (M2 PRESSWIRE via COMTEX) -- The Emerging Stock Report is following Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB) up 57.3% today as it announced the completion of the settlement of the federal and state court class action lawsuits that were filed against the Company and its former executive officers, Thomas P. Motter, Mark M. Miehle, and John W. Hemmer.
Under the terms of settlement of the federal court class action lawsuit, U.S. Fire Insurance Company, which issued a Directors and Officers Liability and Company Reimbursement Policy to Paradigm Medical for the period from July 10, 2002 to July 10, 2003, agreed to pay the sum of $1,507,500 in cash to the class members that purchased securities of the Company during the period between April 17, 2002 and November 4, 2002. Under the terms of settlement of the state court class action lawsuit, U.S. Fire agreed to pay the sum of $625,000 in cash to the class members that purchased shares of Series E Convertible preferred stock on or about July 11, 2001.
Paradigm Medical Industries, Inc., currently develops, manufactures and markets surgical and diagnostic high-tech, proprietary equipment and consumable products for the medical industry. The company specializes in the development and marketing of diagnostic equipment for the ophthalmic market. These products include of topographers, autoperimeters and ultrasonic biomicroscopes and a unique Blood Flow Analyzer help the eye care professional's community diagnose and treat disorders of they eye such as glaucoma, cataracts and age-related macular degeneration. The Company's corporate offices are located in, Salt Lake City, Utah.
Recommended Guidelines for Eye Exams Before age 5:Toddlers should be screened for common childhood problems such as crossed eye, lazy eye, nearsightedness and farsightedness. From puberty to age 39 you should be checked if you experience any eye problems or visual changes such as pain, floaters, flashes of light, blurry vision, or eye injury. During ages 40 to 65 you should be examined every two to four years. Everyone over 65 should be examined every one to two years. People at higher risk for eye diseases need to be examined more often. For example, adults with diabetes should have yearly eye exams. Other people at higher risk include blacks over age 40, people with a family history of eye disease, or those with a history of eye injury.
Source: American Academy of Ophthalmology
Ian Birrell
The Emerging Stock Report profiles emerging growth companies and brings them to the attention of the investment community ahead of the market providing concise analysis and resources required in determining when a stock appears poised for growth.
Subscribers have access to investment research reports, tools for tracking and analyzing, current news, detailed company profiles and ESR "E-Alert" Services. ESR produces comprehensive, timely and dependable research available on the Internet.
Safe Harbor
All material herein was prepared by the Emerging Stock Report (ESR) www.*********************** based upon information believed to be reliable. The information contained herein is not guaranteed by ESR to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ESR is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ESR may receive compensation in cash or shares from independent third parties or from the companies mentioned.
ESR' s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. ESR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ESR undertakes no obligation to update such statements.
CONTACT: Ian Birrell e-mail: ian************************
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info*m2.com.
(C)1994-2005 M2 COMMUNICATIONS LTD
Posted by QuestSolver on :
looking good.....remember.....still an early entry and anywhere in these levels is going to look good in a short time I believe.
new HOD and I do believe this type of movement is going to be the gradual increase.Has anyone else checked out their eye equipment?
Posted by Lucas Brachish on :
I'm so strapped for funds I could only buy a measly 12,500 (* 0.073)... so for now I'm just playing to get my commision money back, and maybe some spare change. Should be fun, though... Didn't wanna completely lose out on another QuestSolver pick.... this way I can at least track the run and see a bit of green on my board... Posted by Enjoys$ on :
is this a good spot to jump in or is it to late?
Posted by Slippery Wing on :
Enjoy,
Why don't YOU tell ME!
Quest found a good gainer today, but remember, those that are quick to rise, are also quick to fall!
-Slip
Posted by Forrestgump on :
Quest whats your next pick?
Posted by QuestSolver on :
another new HOD
Posted by QuestSolver on :
slippery...not today,its just getting back to where it should be and if I remember correctly this ran from .01 flat to .16,gotta look it up again to confirm though.
Posted by Enjoys$ on :
.019
Posted by Slippery Wing on :
You may be right. I'm just going on what I've experienced in the past. Huge, quick run-ups like this are often followed by dips, which has been where I've usually jumped in.
I think this one will dip back, and will be a good place to get it.
If I made 100% in 5 hours worth of trading, I'd be taking a little off the top!
Posted by Louie on :
I always like to hear settlement news with no appeals - I believe this co. may be on the up and up.
I am IN.
Posted by Enjoys$ on :
.02 about to be history
Posted by QuestSolver on :
new HOD and moving up,come on .03...just a taste today you don't have to stay there...just tickle it..LOL
Posted by Enjoys$ on :
Quest, where do you see this at the end of the week?
Posted by SilverStreak on :
Looks like the profit takers have hit
Posted by SilverStreak on :
any ideas ppl
Posted by SilverStreak on :
Quest you still around?
Posted by discosquirrel on :
Whew, looks like i lucked out today. Bought in at 0.0148 and decided to put in a sell order for 0.02 right before i left for the gym at lunch.
Riding free shares now...looking to fill in some more once the dust settles a little
Posted by QuestSolver on :
I am here but trying to make another buy in CLBE right now,not to many chances left at those levels.Looks like it won't touch .03 today but thats OK,tomorrows another day and we are up a good bit.
Posted by Slippery Wing on :
Wow! Good EOD push for all you PMED'ers! Should be a good day tomorrow.
Posted by QuestSolver on :
gapper tomorrow!
good day all! be back soon!
Posted by bmaxingout on :
cci is up money flow is up volume is up rsi is up should have cross over tommorow what else is there to say im in congrats Quest another great pick good luck all bmax,
Posted by Forrestgump on :
Quest what is your next play? for my part I still bet on CTUM.
Posted by SilverStreak on :
Thank you Quest for the nice Pick! Appreciate it!
Posted by Forrestgump on :
Ya Quest very good pick and nice info too.
Posted by Louie on :
Looking good Quest - ask now at .02 - should be an interesting morning.
Posted by QuestSolver on :
gapping and bid and ask up and volume kicked in.If your not in yet you may want to wait for the first dip,I don't think it will stay above .02 to long but will bounce right back over it quick imo.
Posted by QuestSolver on :
waiting for another entry around .016 or so I believe,then bounce over .02...looks like I may not get it
Posted by Forrestgump on :
We may get some news today or this week. I won't be surprise.
Posted by QuestSolver on :
Forrest..not sure but I am in this for an early entry so I hope news holds off until next week or later.Earnings expected early Nov so i am sure we should get a prelude to that.
Posted by Slippery Wing on :
Big time shake in the oil and gas sector this morning! Gotta be patient!
Posted by QuestSolver on :
Greenspan spoke as if ONG was no longer and issue and that will hurt a little,he needs to wake up.
Posted by Forrestgump on :
PMED in Oil sector?
Posted by Slippery Wing on :
Nope, sorry Forrest. Wrong board. My apologies.
-Slip
Posted by QuestSolver on :
no just responding to the post,PMED is a med sector pick
Posted by Louie on :
An entry coming at .00145 possible
Posted by Forrestgump on :
NOW IT IS JUST A MATTER OF TIME....
Posted by QuestSolver on :
hmmmm...might get my set buys here and CLBE!!
Posted by Louie on :
Up and down from .015 to .0195 - 3 times
Posted by Superbee383 on :
Forrest, about that link you sent.. the 'SHO' list? Is that a list of the stocks that the MMs have shorted? Sorry for the dumb question but I could sure use an explanation on trying to understand those MMs!! Thanks!
Posted by Forrestgump on :
Yes
Posted by QuestSolver on :
MAN!!! I was just able to get back online!! we had a power outage since the last time I logged in! And look at these stocks today...oh its definitely a beer night tonight!
everythings in the crapper!!! > Posted by Forrestgump on :
Chart still looking good on long term....will rebounce...
Posted by BULListic on :
Same here Quest...the power company is right outside my window as we speak, but I saw PMED, AMEP, and CLBE all take a crap before the lights went out. Back up and running now and will add to all three positions during this blue light special. Posted by QuestSolver on :
Been off an on the last hour,expecting it to drop out again,looks like they hit an underground service line on the other side of the property.I see all the big rigs there now and here come the white hardhats....LOL...somebodys ass is getting reamed I bet!
Posted by bmaxingout on :
hi all well i didnt buy in today with the pps dropping the way it did but tommorow looks like a good time to get some cheap shares and then hope for a big bounce. i beleive that today we saw a lot of profit taking and then the panic set in shaking out alot of holders that bought in during yesterdays run good luck all
Posted by llatffej on :
holding on PMED, AMEP, AND CLBE.. hoping for green tomorrow
Posted by QuestSolver on :
llatffej
AMEP-CLBE great mid to long hold stocks
PMED imo so far is good for short to mid term play,wait until the financials are released to change unless you notice some major buying just before the release...then you know its good!
as for AMEP
slightly down again in Berlin and hopefully many realize that the energy sector is still under pressure and that the news releases yesterday including Greenspan is nothing but damage control imo. Now they are saying the natural gas issue will not be that bad, it will only increase about 40%. Okay if so I think 40% is still high for less then a 3 month period, hell some would like to have 40% gasins on their stocks within a quarter but think realistically about this....how can they forecast a drop in this prediction? Demand has not declined at all for NG and demand will increase dramatically once everyone puts their heat online and who really knows what king of winter we will have? Have the scientist changed their minds from the previous postings and lionks I provided? I think not. We are in for a bad winter not only this year but for many years to come (no less then 8 years from last year)based on their predictions and that includes more severe hurricane seasons (thats being proven over the last two years already) Either way good luck to us all in out trading but moreso in our personal lives, things are changing quick in our country so always keep a watchful eye open.
as for CLBE
I plan on accumulating another good portion in the .04's and under for the next advancement. this is still a mid to long term play and will be worth holding free shares when the time comes.BIPH virtually did the same identical moves when it was trading in the .09's to .20's. If your interested you should really look out of the box into the Stem Cell issues as to whats going on and how we have advanced and see why its important and maybe you will get a better uderstanding as to why holding a position here or in any other good stem cell stock is worth the patience.
Q
p.s. my posting will be limited today and tomorrow,have a lot of running to do and heading out to Daytona Saturday for Biketoberfest all next week so I won't be around (unless I decide to bring my laptop on vacation with me which is likely...LOL)
Posted by Louie on :
I live in Daytona Beach - BiketOberfest is the best time of year but weather is a little bleak - still pretty warm, though...
Enjoy our little town
louie
quote: have a lot of running to do and heading out to Daytona Saturday for Biketoberfest all next week so I won't be around (unless I decide to bring my laptop on vacation with me which is likely...LOL)
Posted by QuestSolver on :
Wow thanx Louie! I hope the weather clears up next week though because it formally starts next Thursday.As for enjoying your little town that goes without saying,everyone in your neck of the woods are fantastic thats why I have been going down there for about 15 years or os!
Posted by BULListic on :
Nice move back north today...up 30%.
Posted by Forrestgump on :
running....
Posted by Louie on :
Running very Nicely I might add Posted by Louie on :
That was a nice jump up from a.m. - Let's see if we can can do it again... Posted by Forrestgump on :
MMS bring pps down to get shares. PMED on shorting list. Chart look great. When PMED get out of the list, this will run...
Posted by Forrestgump on :
Could be a gapper tomorrow morning. MMs stop to accumulate. Move relativly fast.
Posted by Forrestgump on :
Now upward. Gonna be good.
Posted by Forrestgump on :
So...............
Posted by Superbee383 on :
LMAO.. can't contain the excitement today Forrest? Posted by Forrestgump on :
Lol good one
Posted by popsgotee on :
Any new thoughts on this one? Seems to be setting up for a move up this week. JMHO
Posted by mmalone on :
What's the story here? Very little volume today... any predictions?
Posted by Forrestgump on :
some action today...
Posted by Forrestgump on :
Chart still very bullish but because PMED still on SHO list it won't move til MMs finish to accumulate. Probably last day to get it cheap... Something up right now beacause of the price structure...Could start do run soon. I invite all of you to look at the chart and do some DD before you jump in...Again Very Bullish Chart.
Posted by Forrestgump on :
Bollinger band about to cross upward MA50... MADC flirtinn with 0...about to cross it...
Posted by Forrestgump on :
This one too...On radar
Posted by Lucas Brachish on :
Everyone feeling okay in here? The thread's been quiet...
The PPS seems to be holding steady, with nice little movements to show it's still liquid, if not hot. I feel good about it, although the trend/chart indicators aren't great. They're actually better for the short term than the long, which is interesting since we're looking at this as a somewhat longer play (at least in penny terms) ... but of course some good news will change the indicators overnight for something like this...
Short Term Indicators Average: 20% - Buy 20-Day Average Volume - 3392500
Medium Term Indicators Average: 25% - Sell 50-Day Average Volume - 2212422
Long Term Indicators Average: 67% - Sell 100-Day Average Volume - 1377291
Overall Indicators Average: 24% - Sell
Support: 0.0125 Resistance: 0.0141
AmBull: Sell-If
'Night.
Posted by popsgotee on :
I'll sit in this until it gives me a reason to bail, I like the fact that it seems to be holding here well.
Posted by Before_You_Buy on :
I'm hearing there warrant PMEDW should be moving up again. If you look at the charts PMEDW ran from .01-.16 last time. Why is PMEDW going to move? Appears some money will be transfered from a bank they took put a loan from (Wells fargo) into PMEDW were the company will cash out from. Keep PMEDW on your watch list if you own PMED because she surely ran with no problem last time. 1600% =)
Posted by Lucas Brachish on :
quote:Originally posted by Before_You_Buy: I'm hearing there warrant PMEDW should be moving up again....
That's a good call. PMEDW wasn't on my radar, but it is now. Thanks.
In general, warrants confuse me a bit. According to their last SEC filing, PMED has issued a number of warrants for various things and to various people. Some were for employees, some for investors. And some (I believe) are connected to the litigation against the company. But which of these warrants are being traded as PMEDW? If these warrants are connected to the litigation, then shouldn't they expire now that the lawsuit has been settled? Or, if not, when's the expiration date for the PMEDW warrants... I know that PMED has extended their warrant expiration dates before (PMEDW was scheduled to expire in 2002 but is still around), but I don't know (and was unable to find) all the pertinent details of PMEDW.
Also, of course, there's the key question of what these warrants are actually worth and are potentially worth and the risk involved. (A warrant typically gives the owner the option to buy X number of common stock at a particular price, correct? So what option is this warrant offering...) And I'm not sure why PMEDW's pps would go up just because money is deposited there, when it will presumably be pulled right back out to settle the litigation, etc....
Forgive my naivete in these matters, but trading warrants (and finding solid info on warrants) just seems really tricky to me. On the other hand, it's clear that PMEDW could be quite valuable depending on the answers to the questions above... and the better PMED itself does, the more PMEDW will presumably be worth. So it's definitely worth looking into (especially if you feel PMED is a good buy right now, which I do.)
Big shake..... .011 x .0115 28.5 million o/s and 6 million traded. The MM's drove this down from .0145 to below .012 before any of the volume kicked in...anyone with any theories?
Posted by Forrestgump on :
MMs need shares because PMED is in SHO list since last run...
Posted by JimSC on :
Hi, Bullistic:
This is because some investors put their shares on stop-sale order to protect their investment. This allows the MMs to steal their shares.
Posted by BULListic on :
You know, I'm trying to grasp the SHO list...I can't tell if that's good or bad. If a stock is shorted, eventually any big runup will send the shorters scurying to exit their position, therefore this drives the price up and is good....but is being on the list itself bad?? I've been in pennies on and off for 20 years but haven't come up with an answer for this one yet.
I'm in at .01 flat and haven't sold a share...thinking of adding another 50% since it seems everytime we get to .011 or .012, we get back to .016 or higher.
Posted by BrettStang on :
Is today the day for PMED? I see the stock is now off of the short list, but the volume has been very low lately will that hold it down? I am in for 300k shares so I am waiting for that run to come.
Posted by JimSC on :
JimSC (edicom2k) wrote:
Great entry points for 4 high-growth stocks at bottom:
PMED, CLBE, VTLV, and VMHVF.
Posted by Fairly_New on :
PMEDW -- as well -- needing this one to hold off just till monday Posted by BULListic on :
I think PMED has bottom out at .0097 x .0098, I'm in for another 100k at .0098 and minutes after that, buy orders of 140k, 100k, 100k, and 200k came in within the next 10 minutes....DOMS at 98 and 3 more MM's at 011, one at 0125 and three at 0130...oops another 50k buy...I hope I'm right on this thing ready for a run back up. remember, PMED sitting on 3.8 cents in cash and selling for a penny.
Posted by brendo on :
PMED going up. They are clear of the suits and now off the sho list. Looks good
Posted by QuestSolver on :
I didn't think this one would hit the subs again considering the earnings are due out within a few weeks.
Posted by Deluxer4life on :
Lucas Brachish,
I would stay away from warrents. I got nailed for $7000 worth back in 2003 with AVIIW. Just my advice, I don't want it to happen to anyone else. The market is risky enough.
-Deluxer
Posted by JimSC on :
Status of 4 high-growth stocks:
CLBE: up 21%; news expected next week. VTLV: up 13%; quarter report expected next week. VMHVF: up 10%; news expected next week. PMED: down 12%; great entry point.
Posted by OFFROAD on :
Has anyone heard any new news about AMEP
Posted by Fairly_New on :
Man PMED looks thin ---- Anyone else agree ?
Posted by QuestSolver on :
I totally agree,you can move this one on next to nothing and I plan to add to my position late today or tomorrow and was hoping it stayed in the subs!
Posted by Fairly_New on :
.01 X .012
Posted by BULListic on :
.01 x .0102
Posted by Fairly_New on :
LOL --- sorry there BULL
Posted by BULListic on :
Hey, don't want to pay more than the going rate Posted by Fairly_New on :
Yeah I think its ripe --
L2's anyone -- and anyone know the float ?
Posted by Fairly_New on :
bid moved to .01
Posted by BULListic on :
PERT on the bid at .0099, one at .0097 and two at .0091....SBSH on the ask at .0102 and one at .0104, two at .0105 and two at .011...after .011 it's off to .013. I think the float is around 28 million.
Posted by Fairly_New on :
So whatca thinkin BULL ?
Posted by BULListic on :
I'm thinking I'm in on 300k at .0099 and I'm ready to rumble. We nned that elusive PR and it's been awhile. I usually don't have this much patience, but PMED and AMEP have been my two "long-term" (like 4 weeks) holds. This one moves quick with little volume so we just need a nudge.
Posted by Fairly_New on :
Thats what I'm thinking to -- are you sittin the BID now ?
Posted by Fairly_New on :
looks like getting some action
Posted by Fairly_New on :
volume has doubled
Posted by Fairly_New on :
Confused now -- MM's selling ??
Posted by Fairly_New on :
Damn MM's
Posted by Fairly_New on :
I think people are just itching to see this go, of course I may be wrong ! lol
Posted by Fairly_New on :
Little early morning volume ;0
Posted by BULListic on :
Earnings not due until the third week of November....better get a PR before then of the 80's aren't far off. As I write, there she blows.....0086 x .0086....MEDIC Posted by Fairly_New on :
WTF --
Posted by QuestSolver on :
hmmmmm....I am wondering if they are moving shares now to fill other big block orders.......
Posted by BULListic on :
Well, that flurry is over...who's in too buy more at blue light special pricing?
Posted by BULListic on :
Something is really up....b/a the same, tons of "sales" but can't really tell since the b/a is the same, but I think they are sales, like 300,000 just went buy. Before the spread was quite wide, up to 10% and a little volume moved the stock 20-30%. Are they just moving shares around and if so, is this good or bad. Something isn't normal right now, but can't figure if the immediate future is good or bad. I can't imagine the company is pringting shares, they had a Million in the bank, but I guess they could have blown through that.
Posted by Incognito on :
IMO-Looked like buys on the ask * .0086- ARCA had a seller. Added at .0086
Posted by EverGreen on :
hmmmm they retired the SB2 (for 183m) BUT i suspect the REGDEX is still alive (unknown # shares)
big bloc at bid may confirm that somebody is selling in these situations is really difficult to predict when they will finish
Posted by Fairly_New on :
Upticking with some good volume -- something is stirring Posted by Fairly_New on :
bid & ask thinning .092 X .093
anyone got the L2's
Posted by Fairly_New on :
.093 X .096 -- more buys
Posted by Fairly_New on :
ready for a run ?
Posted by hazel1401 on :
hold your breath, it looks like this is going to fly or drop close to close
Posted by Fairly_New on :
was getting ready to buy and then I say the small 20% profit takers hittin it
Posted by matto on :
sorry i took 20% profit just dont see a full run so in and out!
Posted by Fairly_New on :
Buy back in Posted by Fairly_New on :
buys still kickin on the ask -- come on lets go !
Posted by Fairly_New on :
anyone know the float ?
Posted by JimSC on :
Best time to invest in bio-tek stocks.
JNJ, leading indicator of bio-tek sector stocks, fonnd it's bottom last Friday and ended a 4-month downward trend; this is the best time to enter bio-tek stocks, like BANY, CLBE, and PMED -- they will follow JNJ to a new upward trend.
Posted by Fairly_New on :
good post Jim --- PMED will blastoff -- especially when the quarterly report comes out this month
Posted by QuestSolver on :
PMED and CLBE and of course my baby BIPH!
Posted by JimSC on :
Thanks, Quest, for your DD on DIAAF. It's a very promising one. JimSC (edicom2k)
.
Posted by hazel1401 on :
Is this going to continue going up? or am I going to be broke within the next couple of days ;| Any views on where this will be by the end of nov.?
Posted by QuestSolver on :
10-q's in November
CLBE--due on or around the 16th
AMEP--due on or around the 15th
PMED due on or around the 15th
also FWIW....
DIAAF--due on or around December 22nd.
Posted by Fairly_New on :
Hey Quest,
How are you doing this evening ?
anyway, what is the anticipated PPS after the 10 Q comes out ?
Posted by QuestSolver on :
Fairly New--thats a hard prediction,most pennies drop after the filing but rebound quick unless of course its an extremely outstanding 10-q.The stocks listed are gradual climbers and not real runners imo.They all have good business plans that over time will increase share holder value imo
Posted by Fairly_New on :
Looks like a bit of a run going on here
.01 X .0102 880 K traded
Posted by Fairly_New on :
.0102 X .0109
Posted by QuestSolver on :
looking good......nice and easy.
Posted by OFFROAD on :
DOES ANYBODY KNOW IF THIS IS SOPPOSED TO BE A LONG TERM STOCK OR A SHORT TERM STOCK?
Posted by Fairly_New on :
Good close Posted by QuestSolver on :
short to mid is my play and what a close!!!
Posted by hazel1401 on :
is this going to continue through tomorrow?
should this make it to .02? any thoughts, thanks
Posted by hazel1401 on :
ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION This report contains forward-looking statements and information relating to the Company that is based on beliefs of management as well as assumptions made by, and information currently available to management. These statements reflect its current view respecting future events and are subject to risks, uncertainties and assumptions, including the risks and uncertainties noted throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward-looking statements not to come true as anticipated, believed, projected, expected or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended.
CRITICAL ACCOUNTING POLICIES
REVENUE RECOGNITION. The Company recognizes revenue in compliance with Staff Accounting Bulletin 101, Revenue Recognition in Financial Statements (SAB 101), as revised by Staff Accounting Bulletin No. 104, Revenue Recognition (SAB 104). SAB 101 and SAB 104 detail four criteria that must exist before revenue is recognized:
1. Persuasive evidence of an arrangement exits. Prior to shipment of product, the Company required a signed purchase order and, depending upon the customer, a down payment toward the final invoiced price or full payment in advance with certain international product distributors.
2. Delivery and performance have occurred. Unless the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when the product ships. If the purchase order requires specific installation or customer acceptance, the Company recognizes revenue when such installation or acceptance has occurred. Title to the product passes to its customer upon shipment. This revenue recognition policy does not differ among its various different product lines. The Company guarantees the functionality of its product. If its product does not function as marketed when received by the customer, the Company either makes the necessary repairs on site or has the product shipped to the Company for the repair work. Once the product has been repaired and retested for functionality, it is re-shipped to the customer. The Company provides warranties that generally extend for one year from the date of sale. Such warranties cover the necessary parts and labor to repair the product as well as any shipping costs that may be required. The Company maintains a reserve for estimated warranty costs based on its historical experience and management's current expectations.
3. The sales price is fixed or determinable. The purchase order received from the customer includes the agreed-upon sales price. The Company does not accept customer orders, and therefore does not recognize revenue, until the sales price is fixed.
4. Collectibility is reasonably assured. With limited exceptions, the Company requires down payments on product prior to shipment. In some cases the Company requires payment in full prior to shipment. The Company also performs credit checks on new customers and ongoing credit checks on existing customers. The Company maintains an allowance for doubtful accounts receivable based on historical experience and management's current expectations.
RECOVERABILITY OF INVENTORY. Since its inception, the Company has purchased several complete lines of inventory. In some circumstances the Company has been able to utilize certain items acquired and others remain unused. On a quarterly basis, the Company attempts to identify inventory items that have shown relatively no movement or very slow movement. Generally, if an item has shown little or no movement for over a year, it is determined not to be recoverable and a reserve is established for that item. In addition, if the Company identifies products that have become obsolete due to product upgrades or enhancements, a reserve is established for such products. The Company intends to make efforts to sell these items at significantly discounted prices. If items are sold, the cash received would be recorded as revenue, but there would be no cost of sales on such items due to the reserve that has been recorded. At the time of sale, the inventory would be reduced for the item sold and the corresponding inventory reserve would also be reduced.
RECOVERABILITY OF GOODWILL AND OTHER INTANGIBLE ASSETS. The Company's intangible assets consist of goodwill, product and technology rights, engineering and design costs, and patent costs. Intangibles with a determined life are amortized on a straight-line basis over their determined useful life and are also evaluated for potential impairment if events or circumstances indicate that the carrying amount may not be recoverable. Intangibles with an indefinite life, such as goodwill, are not amortized but are tested for impairment on an annual basis or when events and circumstances indicate that the asset may be impaired. Impairment tests include comparing the fair value of a reporting unit with its carrying net book value, including goodwill. To date, the Company's determination of the fair value of the reporting unit has been based on the estimated future cash flows of that reporting unit.
ALLOWANCE FOR DOUBTFUL ACCOUNTS. The Company records an allowance for doubtful accounts to offset estimated uncollectible accounts receivable. Bad debt expense associated with the increases in the allowance for doubtful accounts is recorded as part of general and administrative expense. The Company's accounting policy generally is to record an allowance for receivables over 90 days past due unless there is significant evidence to support that the receivable is collectible.
GENERAL
The following Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements, which involve risks and uncertainty. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors discussed in this section. The Company's fiscal year is from January 1 through December 31.
The Company is engaged in the design, development, manufacture and sale of high technology diagnostic and surgical eye care products. Given the "going concern" status of the Company, management has focused efforts on those products and activities that will, in its opinion, achieve the most resource efficient short-term cash flow. As seen in the results for the three months ended September 30, 2005, diagnostic products have been the major focus and the Photon and other extensive research and development projects have been put on hold pending future evaluation when the Company's financial position improves. The Company does not focus on a specific diagnostic product or products but, instead, on the entire diagnostic product group.
RESULTS OF OPERATIONS
THREE MONTHS ENDED SEPTEMBER 30, 2005, COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2004 Net sales for the three months ended September 30, 2005 decreased by $349,000, or 39%, to $550,000 as compared to $899,000 for the same period of 2004. This reduction in sales was primarily due to decreased sales of the Blood Flow Analyzer and a softening of sales of the older A Scan and A/B Scan units as well as Dicon perimeters and corneal topographers.
For the three months ended September 30, 2005, sales from the Company's diagnostic products totaled $600,000, or 109% of total revenues, compared to $832,000, or 93% of total revenues for the same period of 2004. These sales were offset by credits that exceeded by $50,000 the combined amount of revenues from parts, disposables, and service during the three months ended September 30, 2005.
Sales of the P40, P45 and new P60 UBM Ultrasound Biomicroscopes increased to $419,000 during the second quarter of 2005, or 76% of total quarterly revenues for the period, compared to $373,000, or 41% of total revenues, for the same period last year. Sales of the Blood Flow Analyzer decreased by $170,000 to $14,000, or 3% of total revenues, for the three months ended September 30, 2005, compared to net sales of $184,000, or 20% of total revenues during the same period in 2004. Sales from the P37 A/B Scan Ocular Ultrasound Diagnostic decreased to $48,000, or 9% of total revenues, for the three month period ended September 30, 2005, down compared to $98,000, or 11% of total revenues, for the same period last year. Combined sales of the LD 400 and TKS 5000 Autoperimeters and the 200 Corneal Topographer were $119,000, or 22% of the total revenues, for the three months ended September 30, 2005, compared to $178,000, or 20% of total revenues, for the same period of 2004.
Sales have been lower for the Company due to an industry slow down. Additionally, sales of the Blood Flow Analyzer decreased due in part from the reorganization of the Company's sales force. The Company anticipates reversing the downward trend in sales through the addition of independent sales representatives, concentrated marketing of the new P60 UBM and other product innovations.
For the three months ended September 30, 2005, gross profit decreased slightly by 4%, to 56% of total revenues, compared to the 60% of total revenues for the comparable period of 2004.
Marketing and selling expenses decreased by approximately $55,000, or 28%, to $143,000, for the three months ended September 30 2005, from $198,000 for the comparable period in 2004. The reduction was due primarily to a reduced number of sales representatives and lower travel related and associated sales expenses and a shift to more independent representatives.
General and administrative expenses increased by $36,000, or 13%, to $312,000 for the three months ended September 30, 2005, from $276,000 for the comparable period in 2004. The expense of the shareholders meeting held on August 12, 2005 was largely responsible for the increase.
Research, development and service expenses increased $48,000, or 29%, for the three months ended September 30, 2005 to $211,000, compared to $163,000 recorded in the same period of 2004. Much of the increase was from the additional development work associated with the P60 and other product line improvements in process.
NINE MONTHS ENDED SEPTEMBER 30, 2005, COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2004 Net sales for the nine months ended September 30, 2005 decreased by $325,000, or 14%, to $1,963,000 as compared to $2,288,000 for the same period of 2004. This reduction in sales was primarily due to reduced sales of the Blood Flow Analyzer (trademark symbol) and a softening of sales of the Dicon (trademark symbol) perimeters and corneal topographers.
For the nine months ended September 30, 2005, sales from the Company's diagnostic products totaled $1,771,000, or 90% of total revenues, compared to $2,084,000, or 91% of total revenues for the same period of 2004. The remaining 10% of sales, or $186,000 during the nine months ended September 30, 2005 was from parts, disposables, and service revenue.
Sales of the P40, P45 and P60 UBM Ultrasound Biomicroscopes increased to $1,096,000 during the nine months ended September 30, 2005, or 56% of total quarterly revenues for the period, compared to $639,000, or 28% of total revenues, for the same period last year. Sales of the Blood Flow Analyzer (trademark symbol) decreased by $399,000 to $76,000, or 4% of total revenues, for the nine months ended September 30, 2005, compared to net sales of $475,000, or 21% of total revenues during the same period in 2004. Sales from the P37 A/B Scan Ocular Ultrasound Diagnostic decreased to $128,000, or 7% of total revenues, for the nine month period ended September 30, 2005, down compared to $229,000, or 10% of total revenues, for the same period last year. Combined sales of the LD 400 and TKS 5000 Autoperimeters and the 200 Corneal Topographer were $471,000, or 24% of the total revenues, for the nine months ended September 30, 2005, compared to $741,000, or 32% of total revenues, for the same period of 2004.
Sales have been lower for the Company due to a variety of reasons. Sales of the Blood Flow Analyzer (trademark symbol) decreased due in part from the reorganization of the Company's sales force. The Company anticipates reversing the downward trend in sales through additional efforts by the Company to gain more widespread support for the Blood Flow Analyzer (trademark symbol) though increased clinical awareness, product development and improved marketing plans.
For the nine months ended September 30, 2005, gross profit decreased by 10%, to 52% of total revenues, compared to the 62% of total revenues for the comparable period of 2004.
Marketing and selling expenses decreased by $38,000, or 7%, to $509,000, for the nine months ended September 30 2005, from $547,000 for the comparable period in 2004. The reduction was due primarily to a reduced number of sales representatives and lower travel related and associated sales expenses.
General and administrative expenses decreased by $47,000, or 5%, to $964,000 for the nine months ended September 30, 2005, from $1,011,000 for the comparable period in 2004. The general and administrative expense savings reflected the on-going results of the Company's cost reduction program and more aggressive budget management procedures implemented in the first nine months of 2005.
In addition, during the first quarter of 2005, the Company issued 515,206 shares of common stock to two shareholders that had purchased shares of the Company's Series G convertible preferred stock in a private offering. Under the terms of the private offering, the Company was required to file a registration statement with the Securities and Exchange Commission for the purpose of registering the common shares issuable to the Series G preferred stockholders upon conversion of their Series G preferred shares and exercise of their warrants. The shares were issued as a penalty for the Company not having a registration statement declared effective within 120 days of the initial closing of the private offering.
Research, development and service expenses increased by $128,000, or 24%, to $671,000 for the nine months ended September 30, 2005, compared to $543,000 in the same period of 2004. Much of the increase was due to the development and regulatory requirements in releasing the new P60 UBM.
LIQUIDITY AND CAPITAL RESOURCES
The Company used $2,491,000 in cash in operating activities for the nine months ended September 30, 2005, compared to $92,000 for the nine months ended September 30, 2004. The increase in cash used for operating activities for the nine months ended September 30, 2005 was primarily attributable to the Company's net loss and decreases in accounts payable and accrued liabilities and an increase in inventory, specifically for the P60. Net cash provided in financing activities was $2,609,000 for the nine months ended September 30, 2005, versus cash used of $42,000 in the same period in 2004. The Company had working capital of $1,221,000 as of September 30, 2005. In January 2005, the Company sold 2,000,000 shares of its common stock to an accredited investor for $150,000 in cash. In the past, the Company has relied heavily upon sales of the Company's common and preferred stock to fund operations. There can be no assurance that such equity funding will be available on terms acceptable to the Company in the future.
As of September 30, 2005, the Company had net operating loss carry- forwards (NOLs) of approximately $48 million. These loss carry-forwards are available to offset future taxable income, if any, and have begun to expire in 2001 and extend for twenty years. The Company's ability to use net operating loss carryforwards (NOLs) to offset future income is dependant upon certain limitations as a result of the pooling transaction with Vismed and the tax laws in effect at the time of the NOLs can be utilized. The Tax Reform Act of 1986 significantly limits the annual amount that can be utilized for certain of these carryforwards as a result of change of ownership.
As of September 30, 2005, the Company had accounts payable of $530,000, a significant portion of which was over 90 days past due. The Company has contacted many of the vendors or companies that have significant amounts of payables past due in an effort to delay payment, renegotiate a reduced settlement payment, or establish a longer-term payment plan. While some companies have been willing to renegotiate the outstanding amounts, others have demanded payment in full. Under certain conditions, including but not limited to judgments rendered against the Company in a court of law, a group of creditors could force the Company into bankruptcy due to its inability to pay the liabilities arising out of such judgments at that time. In addition to the accounts payable noted above, the Company also has non-cancelable capital lease obligations and operating lease obligations that require the payment of approximately $194,000 in 2005, and $14,000 in 2006.
The Company has taken numerous steps to reduce costs and increase operating efficiencies. These steps consist of the following:
1. The Company closed its San Diego facility. In so doing, numerous manufacturing, accounting and management responsibilities were consolidated. In addition, such closure resulted in significant headcount reductions as well as savings in rent and other overhead costs.
2. The Company has significantly reduced the use of consultants, which has resulted in a large decrease to these expenses.
3. The Company has reduced its direct sales force to five representatives, which has resulted in less payroll, travel and other selling expenses.
Because the Company has significantly fewer sales representatives, its ability to generate sales has been reduced.
The Company has taken measures to reduce the amount of uncollectible accounts receivable such as more thorough and stringent credit approval, improved training and instruction by sales personnel, and frequent direct communication with the customer subsequent to delivery of the system. The allowance for doubtful accounts was 2% of total outstanding receivables as of September 30, 2005 and 14% as of December 31, 2004. The allowance for doubtful accounts has decreased from $101,000 at December 31, 2004 to $20,000 at September 30, 2005. The reduction in the allowance for doubtful accounts was the result of the collection of no receivables previously allowed as part of the allowance for doubtful accounts and the write off of $81,000 of receivables against the allowance. The downturn in the economy worldwide has resulted in increased difficulty in collecting certain accounts. Certain international dealers have some aged, unpaid invoices that have not been resolved. The Company has addressed its credit procedures and collection efforts and has instituted changes that require more payments at the time of sale through letters of credit and not on a credit term basis.
The Company intends to continue its efforts to reduce the allowance for doubtful accounts as a percentage of accounts receivable. The Company has ongoing efforts to collect a significant portion of the sales price in advance of the sale or in a timely manner after delivery. During the nine months ended September 30, 2005, the Company had a net recovery of no receivables previously allowed, and during the nine months ended September 30, 2005, the Company did not add to the allowance for doubtful accounts. The Company believes that by requiring a large portion of payment prior to shipment, it has greatly improved the collectibility of its receivables.
The Company carried an allowance for obsolete or estimated non- recoverable inventory of $1,371,000 at September 30, 2005 and $1,559,000 at September 30, 2004, or approximately 51% and 69% of total inventory, respectively. The Company's means of expansion and development of product has been largely from acquisition of businesses, product lines, existing inventory, and the rights to specific products. Through such acquisitions, the Company has acquired substantial inventory, some of which the eventual use and recoverability was uncertain. In addition, the Company has a significant amount of inventory relating to the Photon laser system, which does not yet have FDA approval in order to sell the product domestically. Therefore, the allowance for inventory was established to reserve for these potential eventualities.
On a quarterly basis, the Company attempts to identify inventory items that have shown relatively no movement or very slow movement. Generally, if an item has shown little or no movement for over a year, it is determined not to be recoverable and a reserve is established for that item. In addition, if the Company identifies products that have become obsolete due to product upgrades or enhancements, a reserve is established for such products. The Company intends to make efforts to sell these items at significantly discounted prices. If items are sold, the cash received would be recorded as revenue, but there would be no cost of sales on such items due to the reserve that has been recorded. At the time of sale, the inventory would be reduced for the item sold and the corresponding inventory reserve would also be reduced.
At this time, the Company's Photon (trademark symbol) Laser Ocular Surgery Workstation requires regulatory FDA approval in order to be sold in the United States. Any possible future efforts to complete the clinical trials on the Photon (trademark symbol) in order to file for FDA approval would depend on the Company obtaining adequate funding. The Company estimates that the funds needed to complete the clinical trials in order to obtain the necessary regulatory approval on the Photon (trademark symbol) to be approximately $225,000.
EFFECT OF INFLATION AND FOREIGN CURRENCY EXCHANGE
The Company has not realized a reduction in the selling price of its products as a result of domestic inflation. Nor has it experienced unfavorable profit reductions due to currency exchange fluctuations or inflation with its foreign customers. All sales transactions to date have been denominated in U.S. dollars.
IMPACT OF NEW ACCOUNTING PRONOUNCEMENTS
In December 2003, the FASB issued Interpretation No. 46 ("FIN 46R") (revised December 2003), CONSOLIDATION OF VARIABLE INTEREST ENTITIES, AN INTERPRETATION OF ACCOUNTING RESEARCH BULLETIN NO. 51 ("ARB 51"), which addresses how a business enterprise should evaluate whether it has a controlling interest in an entity through means other than voting rights and, accordingly, should consolidate the entity. FIN 46R replaces FASB Interpretation No. 46 (FIN 46), which was issued in January 2003. Before concluding that it is appropriate to apply ARB 51 voting interest consolidation model to an entity, an enterprise must first determine that the entity is not a variable interest entity (VIE). As of the effective date of FIN 46R, an enterprise must evaluate its involvement with all entities or legal structures created before February 1, 2003, to determine whether consolidation requirements of FIN 46R apply to those entities. There is no grandfathering of existing entities. Public companies must apply either FIN 46 or FIN 46R immediately to entities created after January 31, 2003 and no later than the end of the first reporting period that ends after December 15, 2004. The adoption of FIN 46 had no effect on the Company's consolidated financial position, results of operations or cash flows.
In November 2004, the FASB issued SFAS 151 "Inventory Costs an amendment of ARB No. 43." This statement amends the guidance in ARB No. 43, Chapter 4, "Inventory Pricing," to clarify the accounting for abnormal amounts of idle facility expense, freight, handling costs, and wasted material (spoilage). Paragraph 5 of ARB 43, Chapter 4, previously stated that "[u]nder some circumstances, items such as idle facility expense, excessive spoilage, double freight, and re-handling costs may be so abnormal as to require treatment as current period charges. . . ." This statement requires that those items be recognized as current-period charges regardless of whether they meet the criterion of "so abnormal." In addition, this statement requires that allocation of fixed production overheads to the costs of conversion be based on the normal capacity of the production facilities. The provisions of this statement shall be effective for inventory costs incurred during fiscal years beginning after June 15, 2005. The Company does not believe adoption of SFAS 151 will have any impact on the Company's consolidated financial statements.
In December 2004, FASB issued SFAS 153 "Exchanges of Nonmonetary Assets an amendment of APB Opinion No. 29." The guidance in APB Opinion No. 29, Accounting for Nonmonetary Transactions, is based on the principle that exchanges of nonmonetary assets should be measured based on the fair value of the assets exchanged. The guidance in that opinion, however, included certain exceptions to that principle. This statement amends Opinion 29 to eliminate the exception for nonmonetary exchanges of similar productive assets and replaces it with a general exception for exchanges of nonmonetary assets that do not have commercial substance. A nonmonetary exchange has commercial substance if the future cash flows of the entity are expected to change significantly as a result of the exchange. The Company does not believe adoption of SFAS 153 will have any impact on the Company's consolidated financial statements.
In December 2004, the FASB issued FASB Statement No. 123 (revised 2004), "Share-Based Payment." Statement No. 123 addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. Statement 123 (Registered symbol) requires an entity to recognize the grant-date fair-value of stock options and other equity-based compensation issued to employees in the income statement. The revised statement generally requires that an entity account for those transactions using the fair-value-based method, and eliminates the intrinsic value method of accounting in APB Opinion No. 25, "Accounting for Stock Issued to Employees", which was permitted under Statement 123, as originally issued. The revised statement requires entities to disclose information about the nature of the share-based payment transactions and the effects of those transactions on the financial statements.
Statement No. 123 is effective for public companies that do not file as small business issuers as of the beginning of the first interim or annual reporting period that begins after June 15, 2005. For public companies that file as small business issuers, Statement No. 123 is effective as of the beginning of the first interim or annual reporting period that begins after December 15, 2005 (i.e., the first quarter of 2006 for the Company). All public companies must use either the modified prospective or the modified retrospective transition method. Early adoption of this statement for interim or annual periods for which financial statements or interim reports have not been issued is encouraged. The Company believes that the adoption of this pronouncement may have a material impact on the Company's financial statements.
Posted by hazel1401 on :
not sure if this is good news ;/
Posted by lilhen2005 on :
well hazel, i noticed that it stated that tey're haveing problems paying there creditors, and may have to seek protection under bankruptcy. I don't think that is good. unless they can come up with the cash, i will have to sit this one out. maybe in the future, but not right now.
Posted by hazel1401 on :
i was being slightly sarcastic, sorry
Posted by lilhen2005 on :
sorry hazel thought you were asking a legitimate question. just trying to help.glty, and have some fun.
Posted by hazel1401 on :
np, thanks glty2
Posted by wantmoneyabc on :
has anyone seen the last tarde executed at .39 100 shares
is that right??
Extended Hours (More info...) Last Price Last Size Bid (Size) Ask (Size) Extended Hours
Last Price 0.0079 Bid (size) 0.0078 (x5,000) Today's Change 0.0000 ( 0.00%) Ask (size) 0.0087 (x5,000)
Posted by BULListic on :
.0071 x .0076
Hate to say it, but I'm glad I got out witha small loss in the mid 90's....this wasn't a very good report IMO.
Posted by hazel1401 on :
this is why i never second guess myself, or shouldnt anyways. I got in at .01 and should have got out at .0112 i decided to see if this was going to be a steady UP trend, what a surprise!!! This might be where this stock is going to trade unless they cut the bs holding them back and start over. Advise on whether I should get out at .0055 or just ride it out and waste all of my money. Why do we love investing so much? lol Posted by lilhen2005 on :
hazel i'm not an advisory consultant, but if it were me, i would ride it out. after all the dst settes,you could see a nice litte bouncer. as i have watched this stock for some time i have noticed that it bounces on low volume. a bad Q i'll agree, but could turn around into your favor. low o/s, so no worries of a r/s, and company has good potential to reverse revenues, which could dramatically chage the direction of the pps. jmo, and follow your own trading rules, if you think it's time, then it's time. glty, and i wish you the best.
Posted by hazel1401 on :
Thanks for the advice
I feel i dont have too much to lose at this level anyways.
Posted by BULListic on :
Talk about second guessing...I was in at .01 even and it went to .02 in a couple of days. Pretty much traded between .014 and .018 for numerous days, left it on the table because of the things I liked about it and the price. Then before you know it, it's down to .008 x .0105 and the MM's played this one like you wouldn't believe. Like I stated previously on PMED, they would drop it 15% on a 5k share sell ($50 worth of stock, give me a break). At that time I had enough of those games and called it quits on PMED. Right after that, it jumped back to .0125 and I kicked myself, only to watch it go back to the .008's within hours....didn't have the stomach for this one. Today's quarterly was nothing but mediocre to bad news and I'm not surprised by the drop. I guess the question to ask yourself when you are down a lot on a stock, would I buy it at this price for the first time? If yes, then keep it, if not, sell it and move on. Personally, if I had the time, I'd buy it here at .0055 only because I have a list of 150 stocks and any of them that go down 30% in a day, I buy, if for no other reason, the dead cat bounce. That philosophy works fairly well for me and prevents me from chasing stocks that have gone up to much already. The lack of news from this company, though, will probably prevent this one from going much higher from here for an extened preiod of time, but I can see 10-20% up from here in the coming days-weeks. Unfortunately, I'm not going to have have access to a compuer for about 8 days after Thanksgiving and if I can't babysit these OTCBB's, then I'm outta the market until I can (except for GZFX which I'll hold for at least the next 2-3 months as plenty of news should keep it afloat). Good Luck on your choice.
Posted by JimSC on :
I agree with bullistic that the MMs are taking advnatage of the situation. I have traded this stock several times. 0.0055 is a good buy point, never sell at this price. Hold it, and put a sale order at 0.0108. I am 80% confident, your sale order will go thru within 4 weeks. PMED is a real company with potential. Don't let the MMs take advantage of the situation.
Posted by Lucas Brachish on :
Anyone have new thoughts on this?
QuestSolver -- are you still in? Got an exit strategy?
Posted by QuestSolver on :
I personally averaged down off this 10-q,I didn't expect such a reaction but thats life in the OTC's.The OS is still very small and this could move quick again once they start posting PR's.They do have a real business and inventory thats accountable....time will tell but I am still considering this just a short to maybe mid term play.
Posted by buckstalker on :
Getting some attention...
Posted by Lucas Brachish on :
I tried to average down today but couldn't get a bite at my ask .... which could be a good sign, since it means people aren't too desperate to sell. I'm deep in the red on this one, though.
![[Big Grin]](biggrin.gif)
![[Smile]](smile.gif)
![[Frown]](frown.gif)
![[Roll Eyes]](rolleyes.gif)
![[Razz]](tongue.gif)
![[Cool]](cool.gif)
lol
![[Eek!]](eek.gif)